Mark MooreMark recently served as Executive Director of the International Mouse Phenotyping Consortium (IMPC) and Senior Consultant to National Human Genome Research Institute. For the past 10 years Mark helped guide international consortia to develop genomic resources using mouse ES cells and phenotyping to further the effort to elucidate the function of genes in the mammalian genome. Throughout his career, which began at Genentech, Mark has been interested in the discovery of novel genes involved in human disease and used the mouse as the key model system for drug target discovery and validation. Mark was a Founder of Deltagen and Glialogix. He received his Ph.D. in Biology, studying antibody gene recombination, at Brandeis University and an A.B. from Princeton University in Biochemical Sciences.